Study
ELO: Early Life Origins of Cystic Fibrosis (CF)
Why is this study important?
Cystic Fibrosis (CF) is an inherited genetic condition that effects approximately 1600 children (≤18 years) in Australia. Despite great advances in treatment options and clinical care, development of chronic lung disease with loss of lung function is still the norm for many patients. Substantial evidence exists suggesting that CF lung disease begins in the very early years of life often before the presence of clinical symptoms and before modulator therapies can be prescribed. Compounding this issue is a lack of sensitive techniques that can accurately and quickly detect changes in the lung health of young children with CF.
About the study
To date, this observational study has recruited 232 children and 76 adults from Queensland. Participants are seen at their routine CF clinic appointments, where additional research data is collected. This includes new lung function techniques, urine and blood sampling, and a variety of general and mental health questionnaires.
Our aims are to:
- Explore the suitability of new lung function tests and inflammatory biomarker analysis to detect early changes in CF lung disease.
- Understand individual genetic susceptibility to inflammatory pathways that exacerbate CF lung damage.
- Define the impact of modulator therapies on lung function health.
- Identify children who are at continued risk of poorer lung health outcomes requiring additional support.
- Develop home-monitoring solutions that allow patients and families to better track their lung health in-between hospital visits.
Information for participants
Patients with diagnosed CF, who attend clinics at the Queensland Children’s Hospital, Prince Charles Hospital or Mater Hospital, are eligible to participate in this study.
Most of the information that we collect will form part of your routine clinical care – including clinical history, medication use, lung function (spirometry), microbiology and imaging results.
Research specific data will also be collected at these visits – lung function (multiple breath washout and oscillometry), urine and blood collection for inflammatory analysis, general and mental health questionnaires.
Some participants will be invited to complete a 3-month period of home-monitoring using a portable lung function machine (oscillometry), environmental monitors (to measure air pollution) and urine/nasal cell collections to better understand factors that may contribute to the onset of pulmonary exacerbations in the home. Variability in lung function and certain environmental exposures can significantly worsen lung function in individuals with CF by increasing airway inflammation and mucus production. Weekly zoom check-in sessions will be provided to oversee results and troubleshoot any issues you are having.
If you are interested, please contact Dr Tamara Blake for further information.